Exploring new treatments for pancreatic cancer using advanced models
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitors
This study is looking at a new protein that could help create better treatments for pancreatic cancer by figuring out how it affects cancer cells and their ability to resist drugs, so we can target the cancer more effectively while leaving healthy cells alone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11091485 on NIH RePORTER |
What this research studies
This research investigates a novel signaling protein involved in pancreatic ductal adenocarcinoma (PDAC) and aims to develop more effective treatments. The study utilizes advanced 3D models and in vivo systems to understand how certain proteins affect cancer cell growth and drug resistance. By focusing on selectively targeting cancer cells while sparing surrounding supportive cells, the research seeks to improve treatment outcomes for patients with PDAC. The approach involves testing new compounds that inhibit specific pathways critical for tumor survival.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting potential for success with this novel approach.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Fishel, Melissa L. — Indiana University Indianapolis
- Study coordinator: Fishel, Melissa L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.